{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:16:02Z","timestamp":1781115362897,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005198","name":"China Foundation for Hepatitis Prevention and Control","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660109"],"award-info":[{"award-number":["81660109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clinre.2026.102783","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:12:07Z","timestamp":1770739927000},"page":"102783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Higher incidence of HBeAg seroclearance with tenofovir alafenamide fumarate than entecavir in HBeAg-positive patients with chronic hepatitis B"],"prefix":"10.1016","volume":"50","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajpat Rai","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-5863","authenticated-orcid":false,"given":"Shanfei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2026.102783_bib0001","series-title":"Hepatitis B","year":"2025"},{"issue":"7","key":"10.1016\/j.clinre.2026.102783_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102351","article-title":"Factors influencing pathological changes in the liver tissue in hepatitis B virus carriers with low-level viremia","volume":"48","author":"Fu","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102783_bib0003","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0004","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2026.102783_bib0005","first-page":"1179","article-title":"Hepatitis B virus infection: overview","author":"Li","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102783_bib0006","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14787210.2020.1760843","article-title":"Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis","volume":"18","author":"Geng","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinre.2026.102783_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105876","article-title":"Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon","volume":"227","author":"Huang","year":"2024","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0008","first-page":"57","article-title":"Clinical follow-up of patients with HBeAg positive chronic hepatitis B infection: A long-term observational study","volume":"3","author":"Arslan","year":"2022","journal-title":"Hepatol Forum"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.12370","article-title":"Treating immune-tolerant Hepatitis B","volume":"22","author":"Tseng","year":"2015","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.clinre.2026.102783_bib0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"van Nunen","year":"2003","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.clinre.2026.102783_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169444","article-title":"HBeAg seroconversion in HBeAg-positive chronic Hepatitis B patients receiving long-term nucleos(t)ide analog treatment: A systematic review and network meta-analysis","volume":"12","author":"Xing","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clinre.2026.102783_bib0012","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2024.12.004","article-title":"The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines","volume":"82","author":"Wong","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102783_bib0013","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2026.102783_bib0014","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/liv.15208","article-title":"Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B","volume":"42","author":"Jung","year":"2022","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.clinre.2026.102783_bib0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jvh.13468","article-title":"The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study","volume":"28","author":"Zhang","year":"2021","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.1016\/j.clinre.2026.102783_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70331","article-title":"Impact of Tenofovir Alafenamide on lipid profiles in chronic Hepatitis B patients: systematic review and meta-analysis","volume":"97","author":"Hsu","year":"2025","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102783_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101151","article-title":"A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues","volume":"29","author":"Gu","year":"2024","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102783_bib0018","first-page":"1","article-title":"A commentary on the natural disease progression sequence of chronic Hepatitis B","volume":"4","author":"Liu","year":"2024","journal-title":"Dis Res"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0019","article-title":"Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia","volume":"31","author":"Liu","year":"2023","journal-title":"Chin J Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102783_bib0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jvh.12196","article-title":"Hepatitis B virus depicts a high degree of conservation during the immune-tolerant phase in familiarly transmitted chronic hepatitis B infection: deep-sequencing and phylogenetic analysis","volume":"21","author":"Sede","year":"2014","journal-title":"J Viral Hepat"},{"issue":"7","key":"10.1016\/j.clinre.2026.102783_bib0021","article-title":"Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis","volume":"6","author":"Shin","year":"2024","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.clinre.2026.102783_bib0022","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/MEG.0000000000002598","article-title":"Baseline albumin-bilirubin score: a predictor for HBeAg clearance in patients with chronic hepatitis B after nucleos(t)ide analogue treatment","volume":"35","author":"Zhang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102783_bib0023","first-page":"324","article-title":"3-year treatment of Tenofovir alafenamide vs. Tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"Hou","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102783_bib0024","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jvh.13731","article-title":"Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20\u2009years","volume":"29","author":"Mutimer","year":"2022","journal-title":"J Viral Hepat"},{"issue":"32","key":"10.1016\/j.clinre.2026.102783_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016683","article-title":"Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China","volume":"98","author":"Hu","year":"2019","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.clinre.2026.102783_bib0026","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/HEP.0000000000000413","article-title":"Use of HBV RNA and to predict change in serological status and disease activity in CHB","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0027","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12072-010-9243-x","article-title":"De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of na\u00efve HBeAg-negative chronic hepatitis B patients","volume":"5","author":"Wang","year":"2011","journal-title":"Hepatol Int"},{"issue":"18","key":"10.1016\/j.clinre.2026.102783_bib0028","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.4103\/0366-6999.213969","article-title":"Efficacy of real-world entecavir therapy in treatment-na\u00efve chronic Hepatitis B patients","volume":"130","author":"Xie","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0029","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"34","key":"10.1016\/j.clinre.2026.102783_bib0030","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.12998\/wjcc.v11.i34.8139","article-title":"Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir","volume":"11","author":"Yuan","year":"2023","journal-title":"World J Clin Cases"},{"issue":"8","key":"10.1016\/j.clinre.2026.102783_bib0031","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.clinre.2026.102783_bib0032","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1479-5876-12-183","article-title":"HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients","volume":"12","author":"Yang","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.clinre.2026.102783_bib0033","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2020.07.031","article-title":"Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks","volume":"99","author":"Wang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinre.2026.102783_bib0034","article-title":"Hepatitis B e antigen seroconversion is related with the function of dendritic cells in chronic Hepatitis B Virus infection","volume":"2014","author":"Lin","year":"2014","journal-title":"Gastroenterol Res Pr"},{"issue":"41","key":"10.1016\/j.clinre.2026.102783_bib0035","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.3748\/wjg.v26.i41.6304","article-title":"Efficacy and safety of anti-hepatic fibrosis drugs","volume":"26","author":"Damiris","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0036","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.23323","article-title":"Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.clinre.2026.102783_bib0037","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3748\/wjg.v27.i14.1497","article-title":"Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss","volume":"27","author":"Xue","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102783_bib0038","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102783_bib0039","article-title":"Humoral immunity in hepatitis B virus infection: rehabilitating the B in HBV","volume":"4","author":"Vanwolleghem","year":"2021","journal-title":"JHEP Rep"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:27:26Z","timestamp":1777624046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2210740126000306"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102783","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher incidence of HBeAg seroclearance with tenofovir alafenamide fumarate than entecavir in HBeAg-positive patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102783"}}